GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Bisoprolol tablets (ZEBETA)

Local RX List renal extractBase record retrieved 2026-09-07See the evidence for this drug2 sources available - open source summaries, references and comparisons

ZEBETA

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
High-flux study contradicts older nondialyzable wording

The label mirror assumes little dialysis removal. The 2018 study measured bisoprolol removal with high-flux dialysis, so the dialysis technology and evidence era matter.

Before applying: This small PK study does not validate a replacement dose or outcome benefit. Reconcile dialysis method, dose timing, blood pressure and pulse with the treating team; do not calculate a supplement from a clearance number.

Also check: High-flux study contradicts older nondialyzable wording

Rxlist source

GlobalRPh RX List - ZEBETA

Product / population
Oral bisoprolol single agent; not a bisoprolol/hydrochlorothiazide combination.
Renal measure
Creatinine clearance, mL/min; dialysis method is not specified by this label statement.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

The label dialysis statement conflicts with measured high-flux removal in the separately attributed 2018 trial.

Renal dosing, restrictions and evidence limits

At CrCl below 40 mL/min, the source recommends starting 2.5 mg once daily and titrating cautiously. The mirrored label says limited data suggest bisoprolol is not dialyzable and therefore supplies no replacement dose after dialysis. A separately stored modern high-flux dialysis study challenges that removal assumption. Do not calculate a supplemental dose from the study; review timing, blood pressure and pulse with the dialysis team.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/zebeta-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - ZEBETA

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Oral bisoprolol single agent; not a bisoprolol/hydrochlorothiazide combination.

Renal method: Creatinine clearance, mL/min; dialysis method is not specified by this label statement.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
Professional guidance

Tieu et al. 2018 - bisoprolol high-flux dialyzability

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Adult high-flux HD pharmacokinetic study; not a prescribing trial.

Renal method: Measured high-flux hemodialysis clearance; not residual-kidney CrCl.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

label vs primary research

High-flux study contradicts older nondialyzable wording

The label mirror assumes little dialysis removal. The 2018 study measured bisoprolol removal with high-flux dialysis, so the dialysis technology and evidence era matter.

How to use this: This small PK study does not validate a replacement dose or outcome benefit. Reconcile dialysis method, dose timing, blood pressure and pulse with the treating team; do not calculate a supplement from a clearance number.

GlobalRPh RX List - ZEBETATieu et al. 2018 - bisoprolol high-flux dialyzability

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - ZEBETATieu et al. 2018 - bisoprolol high-flux dialyzability
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/zebeta-drug/

Exact product and population

Oral bisoprolol single agent; not a bisoprolol/hydrochlorothiazide combination.

RDM37-SCOPE-bisoprolol-zebeta · Source section: Selected source product scopeRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - ZEBETA

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Oral bisoprolol single agent; not a bisoprolol/hydrochlorothiazide combination.

Renal method: Creatinine clearance, mL/min; dialysis method is not specified by this label statement.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

At CrCl below 40 mL/min, the source recommends starting 2.5 mg once daily and titrating cautiously. The mirrored label says limited data suggest bisoprolol is not dialyzable and therefore supplies no replacement dose after dialysis. A separately stored modern high-flux dialysis study challenges that removal assumption. Do not calculate a supplemental dose from the study; review timing, blood pressure and pulse with the dialysis team.

RDM37-rxlist-bisoprolol-zebeta-4c06a27263-C1 · Source locator: Dosage: Patients With Renal Or Hepatic Impairment.

Source-specific limits

The label dialysis statement conflicts with measured high-flux removal in the separately attributed 2018 trial.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/zebeta-drug/
Retrieved
2026-09-07
Renal-function method
Creatinine clearance, mL/min; dialysis method is not specified by this label statement.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
9d02073314b926f4ad828191fafde71b012305e0b90647e06338def414611dd4
Separate professional-source layer

University and professional protocols

Professional

Tieu et al. 2018 - bisoprolol high-flux dialyzability

Open original reference

Open / share this exact local source

Tieu et al., Clinical Journal of the American Society of Nephrology · Adult high-flux HD pharmacokinetic study; not a prescribing trial.

Renal method: Measured high-flux hemodialysis clearance; not residual-kidney CrCl.
Source date: 2018
Retrieved: 2026-09-07

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

This randomized, open-label four-way crossover pharmacokinetic study enrolled eight hemodialysis patients and tested single beta-blocker doses. Bisoprolol clearance by the recovery method was 44 mL/min, contradicting the older assumption that it is not dialyzable. The reported observation concerns high-flux hemodialysis; it does not establish a replacement dose, optimal treatment timing, or clinical-outcome benefit. Reconcile the actual dialysis technique and response rather than computing a supplement from clearance alone.

RDM37-professional-bisoprolol-zebeta-0292d9a5c9-C1 · Source locator: Indexed primary-study abstract/methods/results; full-page access blocked on this retrieval.

Source-specific limits

Primary indexed excerpts read (PMID 29519953; DOI 10.2215/CJN.07470717). PMC full-page retrieval was challenged and publisher retrieval required payment. Not a full-text re-review.

Source identity and provenance
Source family
primary_pharmacokinetic_research
Source
https://pmc.ncbi.nlm.nih.gov/articles/PMC5969458/
Retrieved
2026-09-07
Renal-function method
Measured high-flux hemodialysis clearance; not residual-kidney CrCl.
Source date/version
2018
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
4dd078e9a1c1e5e7b3f5762571acece337988523ef133f910fbdfbc04bb3b3e2

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/zebeta-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
e024717786c4514dda378c03d37beb640f688f11f94036d45da3dd27df6b52b6
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report